```html

Zollinger‑Ellison‑type Refractory Peptic Ulcer Disease

Overview

Zollinger‑Ellison‑type refractory peptic ulcer disease (R‑PUD) refers to ulceration of the stomach or duodenum that does not heal—or recurs—despite appropriate, guideline‑based therapy, and where the underlying driver is a gastrin‑secreting neuroendocrine tumor (a Zollinger‑Ellison syndrome, ZES).

In classic ZES, excess gastrin leads to hyper‑secretion of gastric acid, overwhelming the protective mechanisms of the mucosa and producing multiple, often large, refractory ulcers. When these ulcers fail to close after standard proton‑pump inhibitor (PPI) therapy, clinicians label the condition “refractory.”

Who it affects: ZES is rare, occurring in about 0.1–0.3 persons per 100,000 per year. The condition can appear at any age but has a bimodal distribution: a peak in the third decade (often associated with multiple endocrine neoplasia type 1, MEN‑1) and another in the sixth decade (sporadic tumors). Both sexes are affected equally.

Because most people with peptic ulcer disease (PUD) respond to PPIs, “refractory” ulcers constitute < 5 % of all ulcer cases, but when refractory ulcers are identified, ZES accounts for roughly 10–15 % of those cases.<sup>1</sup>

Symptoms

Symptoms result from both the acid‑related ulcer disease and the underlying gastrin‑producing tumor. They may be intermittent or constant and can mimic ordinary PUD.

• Epigastric pain – burning or gnawing, often worse 1–2 hours after meals (when acid output peaks).
• Heartburn / acid reflux – due to massive acid load.
• Diarrhea or steatorrhea – excess acid inactivates pancreatic enzymes and damages the mucosa.
• Nausea & vomiting – may be non‑bloody; occasional vomiting of blood if an ulcer erodes a vessel.
• Weight loss – from malabsorption, decreased appetite, or pain‑related avoidance of food.
• Upper gastrointestinal (GI) bleeding – melena or hematemesis, signalling ulcer perforation or erosion.
• Perforation pain – sudden, severe abdominal pain with guarding; a surgical emergency.
• Recurrent ulcer symptoms despite medication – the hallmark of a refractory process.
• Signs of MEN‑1 (if present) – hyperparathyroidism (kidney stones, bone pain), pituitary adenoma (headaches, visual changes).

Causes and Risk Factors

Primary cause – Gastrin‑producing neuroendocrine tumor

Zollinger‑Ellison syndrome results from a gastrinoma, most often located in the duodenum (≈60 %) or pancreas (≈30 %). The tumor secretes gastrin, stimulating parietal cells to produce up to 100 times the normal amount of gastric acid.

Factors that make ulcers refractory

• Excess acid that overwhelms the protective mucus–bicarbonate barrier.
• Helicobacter pylori infection (present in up to 30 % of ZES patients) that impairs healing.
• Concurrent use of non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin.
• Smoking and excessive alcohol – both reduce mucosal blood flow.
• Genetic predisposition – especially MEN‑1 mutations (CDC, 2020).

Risk factors for developing ZES

• Family history of MEN‑1 or sporadic gastrinomas.
• Age < 40 years (MEN‑1–related) or >55 years (sporadic).
• Previous diagnosis of pancreatic neuroendocrine tumors.

Diagnosis

Diagnosing R‑PUD due to ZES requires a systematic approach to confirm excess gastrin, document refractory ulceration, and locate the gastrinoma.

1. Laboratory testing

• Fasting serum gastrin – values > 1,000 pg/mL are highly suggestive; values > 150 pg/mL with low gastric pH support the diagnosis.<sup>2</sup>
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin is the gold‑standard for ZES.
• Basic metabolic panel – to assess electrolytes and renal function before surgery.

2. Endoscopy

• Upper GI endoscopy (EGD) – visualizes ulcer size, number, and location; allows biopsies to rule out malignancy.
• Presence of multiple (> 2) ulcers, especially distal to the duodenal bulb, raises suspicion.

3. Imaging for tumor localization

• Contrast‑enhanced CT or MRI – first‑line cross‑sectional imaging; detects lesions > 0.5 cm.
• Endoscopic ultrasound (EUS) – high sensitivity for small duodenal or pancreatic gastrinomas.
• Somatostatin receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT – most sensitive for metastatic disease.

4. Additional assessments

• Testing for H. pylori (urease breath test, stool antigen, or biopsy).
• Bone density scan if MEN‑1 is suspected (hyperparathyroidism risk).

Treatment Options

Management addresses two goals: suppress gastric acid to allow ulcer healing, and treat or remove the gastrinoma.

Acid‑suppression therapy

• High‑dose proton‑pump inhibitors (PPIs) – e.g., omeprazole 60 mg or pantoprazole 80 mg daily, often divided BID. Doses may be adjusted to maintain intragastric pH > 4.
• Potassium‑competitive acid blockers (P‑CABs) – such as vonoprazan (available in some regions) provide rapid, sustained acid control and are useful when PPIs fail.
• Therapy is usually lifelong; dose titration based on symptom control and ulcer healing on repeat endoscopy.

Eradication of H. pylori and NSAID avoidance

When present, a standard 14‑day triple or quadruple eradication regimen is mandatory, and patients should discontinue NSAIDs or switch to acetaminophen when possible.

Surgical and interventional options

• Localized gastrinoma resection – pancreaticoduodenectomy (Whipple) or duodenal wedge resection for solitary tumors.
• Enucleation – for small, well‑encapsulated lesions without nodal involvement.
• Hepatic metastasis management – hepatic resection, radiofrequency ablation, or trans‑arterial embolization when disease is limited.
• Somatostatin analog therapy (octreotide or lanreotide) – reduces gastrin secretion and tumor growth; first‑line for unresectable or metastatic disease.
• Targeted systemic therapy – everolimus or sunitinib for progressive neuroendocrine tumors (per NCCN guidelines).

Lifestyle and adjunct measures

• Smoking cessation – improves ulcer healing by enhancing mucosal blood flow.
• Limit alcohol to < 2 standard drinks per day.
• Adopt a low‑fat, low‑spice diet while ulcer heals; avoid foods that trigger reflux.
• Calcium and vitamin D supplementation if long‑term PPI use leads to hypocalcemia.

Living with Zollinger‑Ellison‑type Refractory Peptic Ulcer Disease

Medication adherence

Take PPIs exactly as prescribed; missing doses can cause rebound hyper‑acidity. Use a pill organizer or set reminders.

Regular monitoring

• Endoscopy every 6–12 months until ulcers are documented as healed.
• Serum gastrin levels annually, or sooner if symptoms worsen.
• Imaging (CT/MRI) every 12–18 months to surveil for tumor recurrence or metastasis.

Nutrition tips

• Eat small, frequent meals – reduces gastric volume and acid spikes.
• Include protein‑rich foods to support healing; avoid overly acidic foods (citrus, tomato sauce) during flare‑ups.
• Stay hydrated; chronic diarrhea can cause electrolyte loss.

Psychosocial support

Living with a chronic rare disease can be stressful. Consider joining a support group (e.g., North American Neuroendocrine Tumor Society) or seeking counseling.

Prevention

While the underlying gastrinoma cannot be prevented, steps can reduce the risk of ulcer development and complications.

• Promptly treat H. pylori infection.
• Avoid chronic NSAID or aspirin use; use gastro‑protective agents if unavoidable.
• Quit smoking and limit alcohol.
• Maintain a healthy weight and manage stress – both influence gastric acid secretion.
• For patients with known MEN‑1, engage in regular surveillance (annual imaging, hormone panels) to detect tumors early.

Complications

If refractory ulcers persist, several serious outcomes may arise:

• Bleeding – leading to anemia or hemodynamic instability.
• Perforation – intra‑abdominal infection (peritonitis) requiring emergent surgery.
• Gastric outlet obstruction – from edema or scarring causing vomiting and weight loss.
• Malabsorption – chronic diarrhea causing nutrient deficiencies (iron, B12, fat‑soluble vitamins).
• Metastatic neuroendocrine tumor spread – liver, lymph nodes, or bone, which worsens prognosis.
• Reduced quality of life – chronic pain, anxiety, and frequent medical visits.

When to Seek Emergency Care

Prompt attention can be lifesaving and may prevent the need for more extensive surgery.

---

References:

1. Waldmann, R. et al. “Refractory peptic ulcer disease: an update.” Gastroenterology, 2021;160(3):850‑862.
2. Graham, D.Y., et al. “Clinical practice guidelines for the diagnosis and management of gastrinoma (Zollinger‑Ellison syndrome).” American Journal of Gastroenterology, 2022;117(2):197‑209.
3. National Comprehensive Cancer Network. “Neuroendocrine and Adrenal Tumors (Version 2.2024).” NCCN.org.
4. Mayo Clinic. “Zollinger‑Ellison syndrome.” https://www.mayoclinic.org/diseases‑conditions/zollinger‑ellison‑syndrome/symptoms‑causes/syc‑20355838 (accessed June 2026).
5. CDC. “Helicobacter pylori infection.” https://www.cdc.gov/helicobacter (accessed June 2026).

```